Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals AMPH
$ 23.39 2.86%

Annual report 2025
added 02-26-2026

report update icon

Amphastar Pharmaceuticals Balance Sheet 2011-2026 | AMPH

Annual Balance Sheet Amphastar Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

457 M 457 M 449 M -80.5 M -48.8 M -57 M -26.6 M -36.1 M -18.4 M -34.6 M -25 M -24.1 M -21.4 M -12.2 M -

Long Term Debt

620 M 602 M 590 M 72.8 M 74.8 M 34.2 M 39.4 M 32 M 40.8 M 32.4 M 30.2 M 36.1 M 10.1 M 16 M -

Long Term Debt Current

7.93 M 6.8 M 3.91 M 3 M 2.98 M 3.36 M 3.18 M - - - - - - - -

Total Non Current Liabilities

- - - - - - 69.4 M 42.4 M 50.1 M 37.9 M 34.7 M 44.9 M 21.8 M 24 M -

Total Current Liabilities

158 M 174 M 225 M 94.9 M 104 M 112 M 90 M 107 M 67.2 M 60.6 M 60 M 62.6 M - - -

Total Liabilities

840 M 845 M 873 M 213 M 226 M 183 M 159 M 149 M 117 M 98.5 M 94.6 M 108 M 87.2 M 84 M -

Deferred Revenue

- - - - - - - - - - 643 K 14 M 643 K 642 K -

Retained Earnings

667 M 569 M 409 M 272 M 180 M 118 M 116 M 67.5 M 76.2 M 70.9 M 60.3 M 63.1 M 73.8 M 61.9 M -

Total Assets

1.63 B 1.58 B 1.51 B 742 M 672 M 631 M 587 M 514 M 455 M 428 M 390 M 389 M 339 M 317 M -

Cash and Cash Equivalents

170 M 152 M 145 M 156 M 127 M 94.5 M 73.7 M 86.3 M 65.6 M 72.4 M 66.1 M 67.8 M 53.6 M 50.2 M -

Book Value

789 M 732 M 639 M 529 M 446 M 449 M 428 M 364 M 337 M 329 M 296 M 282 M 252 M 233 M -

Total Shareholders Equity

789 M 732 M 639 M 529 M 446 M 449 M 381 M 332 M 337 M 329 M 296 M 282 M 252 M 233 M -

All numbers in USD currency

Quarterly Balance Sheet Amphastar Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

609 M 608 M 604 M 602 M 596 M 587 M - 590 M 653 M - 72.9 M 72.8 M - 73.9 M 74.3 M 74.8 M 75.6 M 30.5 M 32.3 M 45.9 M 34.2 M 34.2 M 34.2 M 46.3 M 39.4 M 39.4 M 39.4 M 49.1 M 32 M 32 M 32 M 45.7 M 40.8 M 40.8 M 40.8 M 36 M 32.4 M 32.4 M 32.4 M 40.3 M 30.2 M 30.2 M 30.2 M 42.7 M 36.1 M 36.1 M 36.1 M 10.1 M 10.1 M 10.1 M - - - - - - - - -

Total Liabilities

889 M 858 M 875 M 845 M 818 M 778 M - 873 M 949 M - 225 M 213 M - 224 M 237 M 226 M 222 M 199 M 195 M 183 M 183 M 183 M 183 M 159 M 159 M 159 M 159 M 149 M 149 M 149 M 149 M 117 M 117 M 117 M 117 M 98.5 M 98.5 M 98.5 M 98.5 M 94.6 M 94.6 M 94.6 M 94.6 M 108 M 108 M 108 M 108 M 87.2 M 87.2 M 87.2 M - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 830 K 1.66 M 643 K 643 K 643 K 643 K 643 K 14 M 14 M - - - - - - - - - - - - - -

Retained Earnings

642 M 625 M 594 M 569 M 531 M 490 M - 409 M 373 M - 298 M 272 M - 222 M 205 M 180 M 161 M 131 M 123 M 118 M 118 M 118 M 118 M 116 M 116 M 116 M 116 M 67.5 M 67.5 M 67.5 M 67.5 M 72.6 M 72.6 M 76.2 M 76.2 M 70.9 M 70.9 M 70.9 M 70.9 M 60.3 M 60.3 M 60.3 M 60.3 M 63.1 M 63.1 M 63.1 M 63.1 M 73.8 M 73.8 M 73.8 M - - - - - - - - -

Total Assets

1.67 B 1.62 B 1.63 B 1.58 B 1.55 B 1.49 B - 1.51 B 1.54 B - 774 M 742 M - 724 M 716 M 672 M 652 M 666 M 646 M 631 M 631 M 631 M 631 M 587 M 587 M 587 M 587 M 514 M 514 M 514 M 514 M 451 M 451 M 455 M 455 M 428 M 428 M 428 M 428 M 390 M 390 M 390 M 390 M 389 M 389 M 389 M 389 M 339 M 339 M 339 M - - - - - - - - -

Cash and Cash Equivalents

216 M 188 M 183 M 152 M 192 M 190 M 201 M 144 M 271 M 151 M 177 M 156 M 157 M 166 M 173 M 126 M 107 M 125 M 102 M 94.5 M 92.6 M 92.6 M 92.6 M 73.7 M 73.7 M 73.7 M 73.7 M 86.3 M 86.3 M 86.3 M 86.3 M 65.6 M 65.6 M 65.6 M 65.6 M 72.4 M 72.4 M 72.4 M 72.4 M 66.1 M 66.1 M 66.1 M 66.1 M 67.8 M 67.8 M 67.8 M 67.8 M 53.6 M 53.6 M 53.6 M - 50.2 M - - - 53.7 M - - -

Book Value

777 M 757 M 751 M 732 M 728 M 713 M - 639 M 595 M - 549 M 529 M - 499 M 480 M 446 M 430 M 467 M 451 M 449 M 449 M 449 M 449 M 428 M 428 M 428 M 428 M 364 M 364 M 364 M 364 M 334 M 334 M 337 M 337 M 329 M 329 M 329 M 329 M 296 M 296 M 296 M 296 M 282 M 282 M 282 M 282 M 252 M 252 M 252 M - - - - - - - - -

Total Shareholders Equity

777 M 757 M 751 M 732 M 728 M 713 M 672 M 639 M 595 M 589 M 549 M 529 M 505 M 499 M 480 M 446 M 430 M 467 M 451 M 449 M 402 M 402 M 402 M 381 M 381 M 381 M 381 M 332 M 332 M 332 M 332 M 334 M 334 M 337 M 337 M 329 M 329 M 329 M 329 M 296 M 296 M 296 M 296 M 282 M 282 M 282 M 282 M 252 M 252 M 252 M - 233 M - - - 209 M - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Amphastar Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
BioNTech SE BioNTech SE
BNTX
$ 95.5 -3.88 % $ 27.2 B germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.35 0.72 % $ 3.7 B usaUSA
Galapagos NV Galapagos NV
GLPG
$ 28.39 -0.13 % $ 2.69 B belgiumBelgium
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.27 0.49 % $ 6.83 B spainSpain
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.5 5.42 % $ 5.76 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.97 -7.51 % $ 152 M germanyGermany
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.42 -0.3 % $ 2.98 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.4 -2.1 % $ 235 M franceFrance
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 52.38 -2.24 % $ 4.71 B schweizSchweiz
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.64 4.46 % $ 436 M britainBritain
Inventiva S.A. Inventiva S.A.
IVA
$ 5.42 2.85 % $ 138 M franceFrance
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA